| Detected | Trial | Change |
|---|---|---|
| 2026-06-05 | NCT04954820 Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal… |
date change Primary completion pushed: 2031-10 -> 2033-10 |
| 2026-06-05 | NCT04954820 Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal… |
date change Completion pushed: 2031-10 -> 2033-10 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT03972488 | Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade… | Gastro-enteropancreatic Neuroendocrine Tumor | Active, Not Recruiting |
| Phase 2 | |||
| NCT04082520 | Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam… | Grade 1 Meningioma | Recruiting |
| NCT05583708 | Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy… | Merkel Cell Carcinoma | Recruiting |
| NCT05691465 | Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177… | Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation | Recruiting |
| NCT05773274 | Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With… | Metastatic Digestive System Neuroendocrine Tumor G1 | Recruiting |
| NCT04954820 | Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal… | Neuroendocrine Tumors | Recruiting |
| NCT04529044 | 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer | Anatomic Stage IV Breast Cancer AJCC v8 | Recruiting |
| NCT04665739 | Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced… | Advanced Lung Neuroendocrine Tumor | Recruiting |
| NCT03971461 | Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk… | Meningioma | Active, Not Recruiting |
| NCT05724108 | Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted… | Metastatic Neuroendocrine Tumor | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT05278208 | Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors | High Grade Glioma | Recruiting |
| NCT05142696 | A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With… | Extensive Stage Small Cell Lung Cancer | Active, Not Recruiting |
| Phase 1 | |||
| NCT06663072 | Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic… | Metastatic Pancreatic Neuroendocrine Tumor | Recruiting |
| NCT07150546 | Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors. | Digestive System Neuroendocrine Tumor | Recruiting |
| NCT05687123 | Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in… | Metastatic Pancreatic Neuroendocrine Tumor | Recruiting |
| NCT06122610 | Using Novel Imaging to More Safely Treat Neuroendocrine Tumors | Neuroendocrine Tumors | Recruiting |
| NCT04750954 | Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual… | Neuroendocrine Neoplasm | Active, Not Recruiting |
| NCT05109728 | A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in… | Glioblastoma | Active, Not Recruiting |
| NCT04234568 | Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based… | Metastatic Digestive System Neuroendocrine Neoplasm | Active, Not Recruiting |
| NCT06379217 | NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted… | Metastatic Neuroendocrine Prostate Cancer | Active, Not Recruiting |
| Early Phase 1 | |||
| NCT04544098 | Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary… | Neuroendocrine Tumors | Active, Not Recruiting |